Founders Fund VI Management LLC purchased a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics comprises […]
Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for 80.8% of Founders Fund V Management […]
HC Wainwright assumed coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research report sent to investors on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 […]
HC Wainwright began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at […]
Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for Cyclo Therapeutics in a research note issued to investors on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a […]